The effect of rosuvastatin on insulin sensitivity and pancreatic beta-cell function in nondiabetic renal transplant recipients

Sharif, Adnan, Ravindran, Vinod, Moore, R., Dunseath, Gareth John, Luzio, Stephen Denis, Owens, David Raymond and Baboolal, Kesh ORCID: https://orcid.org/0000-0002-3688-9353 2009. The effect of rosuvastatin on insulin sensitivity and pancreatic beta-cell function in nondiabetic renal transplant recipients. American Journal of Transplantation 9 (6) , pp. 1439-1445. 10.1111/j.1600-6143.2009.02644.x

Full text not available from this repository.

Abstract

Interventions to attenuate abnormal glycemia posttransplantation are required. In addition, surrogate markers of declining glycemic control are valuable. Statins may have pleiotropic properties that attenuate abnormal glucose metabolism. We hypothesized statinswould improve glucosemetabolism and HbA1c would be advantageous as a surrogate for worsening glycemia. We conducted a prospective, randomized, placebo controlled, crossover study in 20 nondiabetic renal transplant recipients at low risk for NODAT and compared effects of rosuvastatin on insulin secretion/ sensitivity. Mathematical model analysis of an intravenous glucose tolerance test determined firstphase insulin secretion, insulin sensitivity and disposition index. Second-phase insulin secretion was determined with a meal tolerance test. Biochemical/clinical parameters were also assessed. Rosuvastatin significantly improved total cholesterol (−30%, p < 0.001), LDL cholesterol (−44%, p < 0.001) and triglycerides (−19%, p = 0.013). C-reactive protein decreased but failed to achieve statistical significance (−31%, p = 0.097). Rosuvastatin failed to influence any glycemic physiological parameter, although an inadequate timeframe to allow pleiotropic mechanisms to clinically manifest raises the possibility of a type II statistical error. On multivariate analysis, glycated hemoglobin (HbA1c) correlated with disposition index (R2 = 0.201, p = 0.006), first-phase insulin secretion (R2 = 0.106, p = 0.049) and insulin sensitivity (R2 =0.136, p=0.029). Rosuvastatin fails to modify glucose metabolism in lowrisk patients posttransplantation but HbA1c is a useful surrogate for declining glycemic control.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General)
Uncontrolled Keywords:	Glucose; insulin; insulin resistance; insulin secretion; statins; transplantation
Publisher:	Wiley-Blackwell
ISSN:	1600-6135
Last Modified:	06 Nov 2022 13:41
URI:	https://orca.cardiff.ac.uk/id/eprint/27641

Citation Data

Cited 17 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item